CD44 as a drug delivery target in human cancers: where are we now?

Area of Science:

• Oncology
• Molecular Biology
• Drug Delivery Systems

Background:

• Cancer drug targeting aims to selectively deliver therapeutics to tumors while sparing normal tissues to reduce toxicity and enhance efficacy.
• CD44, a transmembrane proteoglycan, has been investigated as a target for developing cancer-specific drug delivery systems.
• Preclinical research indicated CD44's potential as a viable target for targeted cancer therapies.

Discussion:

• Despite promising preclinical data, two clinical trials, including a Phase III trial, yielded disappointing results for CD44-targeted cancer treatment.
• Potential reasons for clinical trial failures are explored, including complexities of CD44 expression and tumor microenvironment interactions.
• The limitations and challenges associated with using CD44 as a universal cancer target are discussed.

Key Insights:

• The transition from promising preclinical findings to clinical trial failures highlights critical gaps in understanding CD44 biology in cancer.
• Clinical efficacy of CD44-targeted therapies may be hindered by factors not fully recapitulated in preclinical models.
• Re-evaluation of CD44 as a sole target for drug delivery is warranted.

Outlook:

• Future research should focus on elucidating the precise role of CD44 isoforms and their interactions in diverse cancer types.
• Development of novel strategies that account for tumor heterogeneity and the tumor microenvironment is crucial for successful CD44-targeted therapies.
• Exploring combination therapies or alternative targeting approaches may offer new avenues for CD44-based cancer treatment.